Reported about 11 hours ago
Tempus AI, Inc. (NASDAQ:TEM) has emerged as a leading IPO performer, with stock prices increasing after a strong second-quarter revenue of $314.6 million, up 89.6%, primarily due to significant growth in Genomics revenue. Following the FDA's 510(k) clearance for its AI-powered Tempus Pixel cardiac imaging platform, H.C. Wainwright raised its stock price target from $90 to $98, reflecting the company's upward trajectory since its IPO, achieving a growth of 111.50%. Founded in 2015, Tempus AI is at the forefront of integrating artificial intelligence within healthcare to enhance precision medicine.
Source: YAHOO